CoChat

ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance

Open access

The DOI matches its Crossref record; 63 of the 64 references it cites were found in a registry or an index.

Abstract

Hypertriglyceridemia results from accumulation of triglyceride (TG)-rich lipoproteins (TRLs) in the circulation and is associated with increased CVD risk. ApoC-III is an apolipoprotein on TRLs and a prominent negative regulator of TG catabolism. We recently established that in vivo apoC-III predominantly inhibits LDL receptor-mediated and LDL receptor-related protein 1-mediated hepatic TRL clearance and that apoC-III-enriched TRLs are preferentially cleared by syndecan-1 (SDC1). In this study, we determined the impact of apoE, a common ligand for all three receptors, on apoC-III metabolism using apoC-III antisense oligonucleotide (ASO) treatment in mice lacking apoE and functional SDC1 ( Apoe −/− Ndst1 f/f Alb-Cre + ). ApoC-III ASO treatment significantly reduced plasma TG levels in Apoe −/− Ndst1 f/f Alb-Cre + mice without reducing hepatic VLDL production or improving hepatic TRL clearance. Further analysis revealed that apoC-III ASO treatment lowered plasma TGs in Apoe −/− Ndst1 f/f Alb-Cre + mice, which was associated with increased LPL activity in white adipose tissue in the fed state. Finally, clinical data confirmed that ASO-mediated lowering of APOC-III via volanesorsen can reduce plasma TG levels independent of the APOE isoform genotype. Our data indicate that apoE determines the metabolic impact of apoC-III as we establish that apoE is essential to mediate inhibition of TRL clearance by apoC-III and that, in the absence of functional apoE, apoC-III inhibits tissue LPL activity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1194/jlr.m093740

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. Targeting ApoC3 with ASOs in chow-fed Apoe−/−Ndst1f/fAlb-Cre+ mice. A: Apoe−/−Ndst1f/fAlb-Cre+ mice were administered once weekly with apoC-III ASO or control (Ctrl) ASO (50 mg/kg bodyweight) for a period of 8 weeks. Fasting plasma TG levels were measured at the indicated time points. B: ApoC-III ASO-mediated relative change of plasma TG levels compared with control ASO. C: Pooled plasma samples after 4 weeks of ASO treatment were analyzed by size-exclusion FPLC, and TGs in each fraction were measured. Fasting plasma cholesterol levels after apoC-III ASO treatment (D) and relative change in cholesterol compared with control ASO (E). F: FPLC analysis of pooled plasma samples after 4 weeks of ASO treatment followed by cholesterol determination in each fraction. G: VLDLs were isolated by ultracentrifugation and pooled VLDL samples (5 μg of protein per lane) were analyzed by Western blotting with antibodies against apoB, apoC-III, and apoE. Hepatic TG (H) and cholesterol (I) levels as well as relative body weight gain (J) were measured (n = 14–17 per group, values represent mean ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001).
Fig. 1. Targeting ApoC3 with ASOs in chow-fed Apoe−/−Ndst1f/fAlb-Cre+ mice. A: Apoe−/−Ndst1f/fAlb-Cre+ mice were administered once weekly with apoC-III ASO or control (Ctrl) ASO (50 mg/kg bodyweight) for a period of 8 weeks. Fasting plasma TG levels were measured at the indicated time points. B: ApoC-III ASO-mediated relative change of plasma TG levels compared with control ASO. C: Pooled plasma samples after 4 weeks of ASO treatment were analyzed by size-exclusion FPLC, and TGs in each fraction were measured. Fasting plasma cholesterol levels after apoC-III ASO treatment (D) and relative change in cholesterol compared with control ASO (E). F: FPLC analysis of pooled plasma samples after 4 weeks of ASO treatment followed by cholesterol determination in each fraction. G: VLDLs were isolated by ultracentrifugation and pooled VLDL samples (5 μg of protein per lane) were analyzed by Western blotting with antibodies against apoB, apoC-III, and apoE. Hepatic TG (H) and cholesterol (I) levels as well as relative body weight gain (J) were measured (n = 14–17 per group, values represent mean ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001).CC BY · PubMed Central
Fig. 2. ApoC-III ASO decreases plasma TGs in Apoe−/−Ndst1f/fAlb-Cre+ mice on a WD. A: ApoC-III ASO or control (Ctrl) ASO (50 mg/kg bodyweight) was administered to Apoe−/−Ndst1f/fAlb-Cre+ mice fed a WD for 8 weeks, and fasting plasma TG values were measured after 2, 4, and 8 weeks. B: The relative change in plasma TGs upon apoC-III ASO compared with control ASO. C: Size-exclusion FPLC analysis of pooled plasma samples to determine TGs in CR/VLDL, IDL/LDL, and HDL fraction. Measurement of fasting plasma cholesterol levels after apoC-III administration (D) and relative change in cholesterol compared with control ASO (E). F: Pooled plasma samples were analyzed by FPLC and cholesterol was measured in each fraction. G: Western blot detection of apoB, apoC-III, and apoE in pooled VLDL samples (5 μg of protein per lane). Hepatic TG (H) and cholesterol (I) levels as well as relative body weight gain (J) were measured (n = 13, values represent mean ± SEM; *P < 0.05, **P < 0.01).
Fig. 2. ApoC-III ASO decreases plasma TGs in Apoe−/−Ndst1f/fAlb-Cre+ mice on a WD. A: ApoC-III ASO or control (Ctrl) ASO (50 mg/kg bodyweight) was administered to Apoe−/−Ndst1f/fAlb-Cre+ mice fed a WD for 8 weeks, and fasting plasma TG values were measured after 2, 4, and 8 weeks. B: The relative change in plasma TGs upon apoC-III ASO compared with control ASO. C: Size-exclusion FPLC analysis of pooled plasma samples to determine TGs in CR/VLDL, IDL/LDL, and HDL fraction. Measurement of fasting plasma cholesterol levels after apoC-III administration (D) and relative change in cholesterol compared with control ASO (E). F: Pooled plasma samples were analyzed by FPLC and cholesterol was measured in each fraction. G: Western blot detection of apoB, apoC-III, and apoE in pooled VLDL samples (5 μg of protein per lane). Hepatic TG (H) and cholesterol (I) levels as well as relative body weight gain (J) were measured (n = 13, values represent mean ± SEM; *P < 0.05, **P < 0.01).CC BY · PubMed Central
Fig. 3. ApoC-III ASO treatment does not affect hepatic VLDL production and TRL clearance in Apoe−/−Ndst1f/fAlb-Cre+ mice. A: Apoe−/−Ndst1f/fAlb-Cre+ mice were on apoC-III ASO or control (Ctrl) ASO for 4 weeks. Fasted mice (5 h) were given a 250 μl bolus of corn oil by oral gavage to measure fat tolerance. Postprandial TG levels were measured 0, 1, 2, and 3 h after gavage (n = 3 per group). B: Hepatic VLDL production was determined after intravenous injection of Tyloxapol (0.5 mg/g bodyweight) to block lipase activity. TRL uptake and plasma TG levels were measured at the indicated time points (n = 3–5 per group). C: Intestinal lipid absorption was analyzed by intravenous injection of Tyloxapol followed by oral gavage of corn oil (250 μl). Plasma TG levels were measured at the indicated time points (n = 3). D: Hepatic TRL clearance was analyzed by retinyl ester excursion. [3H]retinol (5 μCi) in 250 μl corn oil was orally gavaged and the remaining counts in the plasma were determined by liquid scintillation counting after 2, 4, 6, and 8 h (n = 3). E: Schematic overview of [3H]TRL clearance experiments in vivo. F: Isolated [3H]TRLs enriched (control ASO) or depleted (apoC-III ASO) in apoC-III were injected intravenously into Apoe−/−Ndst1f/fAlb-Cre+ mice on apoC-III ASO (n = 2). Clearance of [3H]TRLs was assessed by measuring the counts remaining in the plasma relative to the counts recovered 1 min after injection (values represent mean ± SEM; *P < 0.05, **P < 0.01).
Fig. 3. ApoC-III ASO treatment does not affect hepatic VLDL production and TRL clearance in Apoe−/−Ndst1f/fAlb-Cre+ mice. A: Apoe−/−Ndst1f/fAlb-Cre+ mice were on apoC-III ASO or control (Ctrl) ASO for 4 weeks. Fasted mice (5 h) were given a 250 μl bolus of corn oil by oral gavage to measure fat tolerance. Postprandial TG levels were measured 0, 1, 2, and 3 h after gavage (n = 3 per group). B: Hepatic VLDL production was determined after intravenous injection of Tyloxapol (0.5 mg/g bodyweight) to block lipase activity. TRL uptake and plasma TG levels were measured at the indicated time points (n = 3–5 per group). C: Intestinal lipid absorption was analyzed by intravenous injection of Tyloxapol followed by oral gavage of corn oil (250 μl). Plasma TG levels were measured at the indicated time points (n = 3). D: Hepatic TRL clearance was analyzed by retinyl ester excursion. [3H]retinol (5 μCi) in 250 μl corn oil was orally gavaged and the remaining counts in the plasma were determined by liquid scintillation counting after 2, 4, 6, and 8 h (n = 3). E: Schematic overview of [3H]TRL clearance experiments in vivo. F: Isolated [3H]TRLs enriched (control ASO) or depleted (apoC-III ASO) in apoC-III were injected intravenously into Apoe−/−Ndst1f/fAlb-Cre+ mice on apoC-III ASO (n = 2). Clearance of [3H]TRLs was assessed by measuring the counts remaining in the plasma relative to the counts recovered 1 min after injection (values represent mean ± SEM; *P < 0.05, **P < 0.01).CC BY · PubMed Central
Fig. 4. ApoC-III inhibition of TRL clearance requires apoE. A–D: Primary hepatocytes were isolated from Apoe−/−Ndst1f/fAlb-Cre+ mice and binding (4°C) and uptake (37°C) of [3H]retinol-labeled apoC-III-enriched and apoC-III-deficient TRL particles were analyzed. A: Binding of [3H]TRLs (100 μg/ml) enriched or deficient in apoC-III was determined after incubation in primary hepatocytes in the absence or presence of apoE at 4°C for 1 h. Binding and uptake was assessed after incubation of [3H]retinol-labeled TRLs at 37°C for 4 h in a dose-dependent manner (10/20/50/100 μg/ml) in the absence (B) and presence (C) of apoE. D: Reconstituted [3H]TRLs (50 μg) were evaluated in their binding and uptake capacity in primary hepatocytes (n = 3 per condition in all experiments, values represent mean ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001).
Fig. 4. ApoC-III inhibition of TRL clearance requires apoE. A–D: Primary hepatocytes were isolated from Apoe−/−Ndst1f/fAlb-Cre+ mice and binding (4°C) and uptake (37°C) of [3H]retinol-labeled apoC-III-enriched and apoC-III-deficient TRL particles were analyzed. A: Binding of [3H]TRLs (100 μg/ml) enriched or deficient in apoC-III was determined after incubation in primary hepatocytes in the absence or presence of apoE at 4°C for 1 h. Binding and uptake was assessed after incubation of [3H]retinol-labeled TRLs at 37°C for 4 h in a dose-dependent manner (10/20/50/100 μg/ml) in the absence (B) and presence (C) of apoE. D: Reconstituted [3H]TRLs (50 μg) were evaluated in their binding and uptake capacity in primary hepatocytes (n = 3 per condition in all experiments, values represent mean ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001).CC BY · PubMed Central
Fig. 5. ApoC-III lowering increased FA uptake in liver and WAT in Apoe−/−Ndst1f/fAlb-Cre+ mice. A: Apoe−/−Ndst1f/fAlb-Cre+ mice were fasted for 5 h. After a 5 min intravenous injection of [3H]triolein-labeled liposyn particles (100 μl), blood and the indicated tissues were harvested (A) and (B) tissue weights were determined (B). [3H]triolein tissue uptake was determined of the homogenized tissues by liquid scintillation counting (n = 4–6). C: [3H]palmitic acid uptake into various tissues of control (Ctrl) ASO- and apoC-III ASO-treated mice was analyzed by retro-orbital injection of 1 μCi (n = 4–6). D: Primary hepatocytes were isolated from mice administered with control ASO or apoC-III ASO and binding and uptake of [14C]oleic acid was assessed in vitro. Hepatocytes were incubated with 0.5 μCi of radiolabeled FAs at 37°C, and incorporation was measured at the indicated time points (n = 3 per condition; values represent mean ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001).
Fig. 5. ApoC-III lowering increased FA uptake in liver and WAT in Apoe−/−Ndst1f/fAlb-Cre+ mice. A: Apoe−/−Ndst1f/fAlb-Cre+ mice were fasted for 5 h. After a 5 min intravenous injection of [3H]triolein-labeled liposyn particles (100 μl), blood and the indicated tissues were harvested (A) and (B) tissue weights were determined (B). [3H]triolein tissue uptake was determined of the homogenized tissues by liquid scintillation counting (n = 4–6). C: [3H]palmitic acid uptake into various tissues of control (Ctrl) ASO- and apoC-III ASO-treated mice was analyzed by retro-orbital injection of 1 μCi (n = 4–6). D: Primary hepatocytes were isolated from mice administered with control ASO or apoC-III ASO and binding and uptake of [14C]oleic acid was assessed in vitro. Hepatocytes were incubated with 0.5 μCi of radiolabeled FAs at 37°C, and incorporation was measured at the indicated time points (n = 3 per condition; values represent mean ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001).CC BY · PubMed Central
Fig. 6. Transcriptomics and metabolomics of hepatocytes from apoC-III ASO-treated Apoe−/−Ndst1f/fAlb-Cre+ mice. A: Volcano-plot depicting a differential gene expression derived from RNA-seq analysis of livers isolated from fasted Apoe−/−Ndst1f/fAlb-Cre+ mice receiving apoC-III ASO or control (Ctrl) ASO for 8 weeks. Genes that were significantly (adjusted P < 0.05) up- or downregulated upon apoC-III ASO are highlighted (excluding Apoc3). B: A heat map showing differentially expressed protein-coding genes with adjusted P-value <0.05 upon apoC-III ASO (left panel, n = 5) compared with control ASO (right panel, n = 4). Heat maps of genes involved in de novo lipogenesis (C) and FA transport (D). E: ApoC-III ASO or control ASO were administered to Apoe−/−Ndst1f/fAlb-Cre+ mice and primary hepatocytes were isolated and incubated with 20 μM U-[13C16]palmitic acid tracer for 1 h and 4 h at 37°C for cellular FA metabolism analysis. After lipid extraction and GC/MS, enrichment of FA from U-[13C16]palmitic acid tracer and total FA composition were determined. F: Total percentage of C16:0 is shown. G: Enrichment of U-[13C16]palmitic acid tracer in metabolites of the TCA cycle (n = 3–4 per condition, values represent mean ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001).
Fig. 6. Transcriptomics and metabolomics of hepatocytes from apoC-III ASO-treated Apoe−/−Ndst1f/fAlb-Cre+ mice. A: Volcano-plot depicting a differential gene expression derived from RNA-seq analysis of livers isolated from fasted Apoe−/−Ndst1f/fAlb-Cre+ mice receiving apoC-III ASO or control (Ctrl) ASO for 8 weeks. Genes that were significantly (adjusted P < 0.05) up- or downregulated upon apoC-III ASO are highlighted (excluding Apoc3). B: A heat map showing differentially expressed protein-coding genes with adjusted P-value <0.05 upon apoC-III ASO (left panel, n = 5) compared with control ASO (right panel, n = 4). Heat maps of genes involved in de novo lipogenesis (C) and FA transport (D). E: ApoC-III ASO or control ASO were administered to Apoe−/−Ndst1f/fAlb-Cre+ mice and primary hepatocytes were isolated and incubated with 20 μM U-[13C16]palmitic acid tracer for 1 h and 4 h at 37°C for cellular FA metabolism analysis. After lipid extraction and GC/MS, enrichment of FA from U-[13C16]palmitic acid tracer and total FA composition were determined. F: Total percentage of C16:0 is shown. G: Enrichment of U-[13C16]palmitic acid tracer in metabolites of the TCA cycle (n = 3–4 per condition, values represent mean ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001).CC BY · PubMed Central
Fig. 7. ApoC-III inhibits lipase activity in WAT from Apoe−/−Ndst1f/fAlb-Cre+ mice. A: Plasma TG levels were measured 3 h after an oral corn oil gavage (250 μl) before and 10 min after an intravenous heparin injection (50 U per mouse) (n = 3). B: Lipoprotein and HL activities were analyzed in post-heparin plasma in mice administered with control (Ctrl) ASO or apoC-III ASO (n = 5–6). C: Fasting NEFA values in mice treated with ASOs for 4 weeks (n = 6–8). D–F: Lipase activity was determined in liver (D), BAT (E), and gWAT (F) isolated from fasted (5 h) or fed Apoe−/−Ndst1f/fAlb-Cre+ mice (n = 4–6). Detection of LPL in liver (25 μg) (G), BAT (20 μg) (H), and gWAT (20 μg) (I) by Western blotting. LPL expression was quantified relative to β-actin (n = 3 per group, values represent mean ± SEM; *P < 0.05, **P < 0.01).
Fig. 7. ApoC-III inhibits lipase activity in WAT from Apoe−/−Ndst1f/fAlb-Cre+ mice. A: Plasma TG levels were measured 3 h after an oral corn oil gavage (250 μl) before and 10 min after an intravenous heparin injection (50 U per mouse) (n = 3). B: Lipoprotein and HL activities were analyzed in post-heparin plasma in mice administered with control (Ctrl) ASO or apoC-III ASO (n = 5–6). C: Fasting NEFA values in mice treated with ASOs for 4 weeks (n = 6–8). D–F: Lipase activity was determined in liver (D), BAT (E), and gWAT (F) isolated from fasted (5 h) or fed Apoe−/−Ndst1f/fAlb-Cre+ mice (n = 4–6). Detection of LPL in liver (25 μg) (G), BAT (20 μg) (H), and gWAT (20 μg) (I) by Western blotting. LPL expression was quantified relative to β-actin (n = 3 per group, values represent mean ± SEM; *P < 0.05, **P < 0.01).CC BY · PubMed Central
Fig. 8. ApoC-III inhibition does not affect the size distribution of lipoprotein subclasses. Plasma samples of fasted (A) and fed (Β) Apoe−/−Ndst1f/fAlb-Cre+ mice on a chow diet administered with apoC-III ASO or control (Ctrl) ASO over 8 weeks were collected. Concentrations of plasma lipoprotein subclasses were measured by particle-size intervals from HDL to VLDL using ion mobility. The data represent HDL subclasses and intermediates, and show LDL, IDL, and VLDL subclasses (n = 3 pooled samples, three samples per pool, values represent mean ± SEM).
Fig. 8. ApoC-III inhibition does not affect the size distribution of lipoprotein subclasses. Plasma samples of fasted (A) and fed (Β) Apoe−/−Ndst1f/fAlb-Cre+ mice on a chow diet administered with apoC-III ASO or control (Ctrl) ASO over 8 weeks were collected. Concentrations of plasma lipoprotein subclasses were measured by particle-size intervals from HDL to VLDL using ion mobility. The data represent HDL subclasses and intermediates, and show LDL, IDL, and VLDL subclasses (n = 3 pooled samples, three samples per pool, values represent mean ± SEM).CC BY · PubMed Central
Fig. 9. Volanesorsen lowers plasma TG levels independent of allelic APOE expression in a hypertriglyceridemia cohort. In a randomized double-blind placebo-controlled dose-ranging phase 2 study, placebo or volanesorsen (100–300 mg) was administered once weekly to patients with different allelic apoE background. Plasma APOC-III (A), plasma TG levels (B), and plasma non-HDL-C levels (C) were measured at baseline and after 85 days of either placebo or volanesorsen treatment in patients homozygous for APOE2 (E2/E2), APOE3 (E3/E3), and APOE4 (E4/E4), respectively (E2/E2: placebo n = 4, volanesorsen n = 3; E3/E3: placebo n = 7, volanesorsen 100 mg n = 3, 200 mg n = 7, 300 mg n = 3; E4/E4: placebo n = 1, volanesorsen n = 4; values represent mean ± SEM, data are shown for patients on monotherapy combined with fibrates).
Fig. 9. Volanesorsen lowers plasma TG levels independent of allelic APOE expression in a hypertriglyceridemia cohort. In a randomized double-blind placebo-controlled dose-ranging phase 2 study, placebo or volanesorsen (100–300 mg) was administered once weekly to patients with different allelic apoE background. Plasma APOC-III (A), plasma TG levels (B), and plasma non-HDL-C levels (C) were measured at baseline and after 85 days of either placebo or volanesorsen treatment in patients homozygous for APOE2 (E2/E2), APOE3 (E3/E3), and APOE4 (E4/E4), respectively (E2/E2: placebo n = 4, volanesorsen n = 3; E3/E3: placebo n = 7, volanesorsen 100 mg n = 3, 200 mg n = 7, 300 mg n = 3; E4/E4: placebo n = 1, volanesorsen n = 4; values represent mean ± SEM, data are shown for patients on monotherapy combined with fibrates).CC BY · PubMed Central
Fig. 10. The role of apoC-III on lipoprotein metabolism varies depending on apoE. Schematic representation of how apoE determines the metabolic fate of apoC-III in TG metabolism by shifting apoC-III’s versatile role from attenuating hepatic TRL clearance to LPL inhibition.
Fig. 10. The role of apoC-III on lipoprotein metabolism varies depending on apoE. Schematic representation of how apoE determines the metabolic fate of apoC-III in TG metabolism by shifting apoC-III’s versatile role from attenuating hepatic TRL clearance to LPL inhibition.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 59

Metadata

Authors
Ramms, B., Patel, S., Nora, C., Pessentheiner, A. R., Chang, M. W., Green, C. R., Golden, G. J., Secrest, P., Krauss, R. M., Metallo, C. M., Benner, C., Alexander, V. J., Witztum, J. L., Tsimikas, S., Esko, J. D., & Gordts, P. L. S. M.
Affiliations
  • Bielefeld University (DE)
  • University of California San Diego (US)
  • Ionis Pharmaceuticals (United States) (US)
Corresponding author
  • Ramms, Bastian
  • Gordts, Philip L.S.M.
Venue
Journal of Lipid Research
Publisher
Elsevier BV
Published
2019-08
Volume
60
Issue
8
Pages
1379-1395
ISSN
0022-2275 (ISSN-L)
OpenAlex
W2945419995
Cited by
59
References
64
Citations by year
2026: 2 · 2025: 3 · 2024: 7 · 2023: 12 · 2022: 6 · 2021: 12 · 2020: 11 · 2019: 6
FWCI
6.32
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Lipid Research (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • eScholarship (California Digital Library) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
Funders
  • American Heart Association (17PRE33410619, 15BGIA25550111)
  • National Institute of General Medical Sciences (GM33063)
  • National Heart, Lung, and Blood Institute (P01 HL107150)
  • Ionis Pharmaceuticals, Inc.
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords
apolipoprotein C-III, antisense oligonucleotides, lipoprotein lipase, triglyceride-rich lipoproteins, apolipoprotein E, syndecan-1, hypertriglyceridemia, volanesorsen, white adipose tissue, triglyceride catabolism, ApoE-deficient mice
MeSH terms
Mice, Knockout, ApoE, Animals, Apolipoproteins E, Lipoprotein Lipase, Receptors, LDL, Triglycerides, Mice, Apolipoprotein C-III

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.